Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 8/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301765 | 0.86 | TSHR (0.36) | TSHRKMT2AMEN1 | |
| SCHEMBL3307394 | 0.86 | TSHR (0.36) | TSHRKMT2AMEN1 | |
| SCHEMBL6798706 | 0.86 | TSHR (0.36) | TSHRKMT2AMEN1 | |
| SCHEMBL8983770 | 0.86 | TSHR (0.36) | TSHRKMT2AMEN1 | |
| SCHEMBL6607996 | 0.82 | AGTR2 (0.36) | AGTR2CYP3A4KMT2AMEN1MTNR1A | |
| SCHEMBL8867224 | 0.78 | MMP2 (0.39) | CYP3A4TSHR | |
| SCHEMBL8866598 | 0.78 | MMP2 (0.39) | CYP3A4TSHR | |
| SCHEMBL13390232 | 0.77 | TSHR (0.36) | TSHR | |
| SCHEMBL3301971 | 0.75 | HSD17B10 (0.38) | CYP3A4CYP1A2HSD17B10 | |
| SCHEMBL3304315 | 0.75 | HSD17B10 (0.38) | CYP3A4CYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0590789-B9 | Excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-0590789-B1 | Excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 2003-03-12 | — | — | EP | disclosed |
| US-5670516-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-5648492-A | Process for preparing isoquinoline compounds | ELI LILLY AND COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5637712-A | CATALYTIC HYDROGENNATION | ELI LILLY AND COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| US-5399696-A | Excitatory amino acid receptor antagonists; nervous system disorders | ELI LILLY AND COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| US-5356902-A | Central nervous system disorders | ELI LILLY AND COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| US-5284957-A | Substituted 1H- or 2H-tetrazoles | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |